NASDAQ: PMCB - PharmaCyte Biotech, Inc.

六个月盈利: -30.89%
股息率: 0.00%
部门: Healthcare

促销时间表 PharmaCyte Biotech, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.

更多详情
The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2010-09-17
ISIN US71715X2036
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://pharmacyte.com
Цена ао 1.49
每日价格变化: -4.35% (1.38)
每周价格变化: -16.46% (1.58)
每月价格变化: -23.26% (1.72)
3个月内价格变化: -15.92% (1.57)
六个月内的价格变化: -30.89% (1.91)
每年价格变化: -44.3% (2.37)
3年内价格变化: -45.68% (2.43)
5年内价格变化: +2 488.24% (0.051)
年初以来价格变化: -14.84% (1.55)
所有参数

低估

姓名 意义 年级
P/S 0 0
P/BV 0.514 10
P/E 60.86 1
EV/EBITDA -89.49 0
全部的: 3.63

效率

姓名 意义 年级
ROA, % 0.5012 1
ROE, % 0.5949 1
全部的: 0.3333

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0.0212

责任

姓名 意义 年级
Debt/EBITDA 0 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -98.14 0
盈利能力 Ebitda, % -108.78 0
盈利能力 EPS, % -1344.13 0
全部的: 0
更多详情

机构 体积 分享, %
K2 Principal Fund, L.P. 304613 0.01
Geode Capital Management, LLC 215637 0.01
Vanguard Group Inc 171335 0.01
Equitec Proprietary Markets LLC 82727 0
Sabby Management, LLC 82373 0
Renaissance Technologies, LLC 38100 0
Dimensional Fund Advisors LP 29307 0
Blackrock Inc. 28769 0
Citadel Advisors Llc 28618 0
Schonfeld Strategic Advisors LLC 23200 0

ETF分享, %本年盈利能力, %股息, %
Dimensional U.S. Targeted Value ETF 0.00013 26.01 1.93487
Dimensional U.S. Core Equity 2 ETF 0.00006 30.76 1.47098
028.391.7



导师 职称 支付 出生年份
Mr. Joshua N. Silverman Interim CEO, Interim President & Interim Chairman 197.92k 1970 (55 年)
Mr. Carlos A. Trujillo CPA, CPA Chief Financial Officer 380k 1958 (67 年)
Dr. Jose L. Iglesias M.D. Consulting Chief Medical Officer N/A 1957 (68 年)
Dr. Hans-Peter Hammes Member of Medical & Scientific Advisory Board and Consultant N/A

地址: United States, Las Vegas. NV, 3960 Howard Hughes Parkway - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://pharmacyte.com